SCHEDULE 13G/A: David Capital Partners Discloses 4.87% Passive Stake in LifeCore Biomedical

David Capital Partners, LLC and David Capital Partners Fund, LP have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.87% in LifeCore Biomedical, Inc. as of December 31, 2024.

Summary

• David Capital Partners, LLC and David Capital Partners Fund, LP (collectively, "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing indicates that the Reporting Persons beneficially own 1,803,000 shares of Common Stock in LIFECORE BIOMEDICAL, INC. \DE\.
• This ownership represents 4.87% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 37,025,331 shares of Common Stock outstanding as of December 26, 2024, as reported in the Issuer's Form 10-Q filed on January 2, 2025.
• David Capital Partners, LLC, an Investment Manager, directly holds these shares on behalf of its advisory clients.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the Issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine regulatory disclosure of a passive ownership stake and does not contain information that would inherently be considered positive or negative for the company's operations or financial health. It simply updates the public record on an institutional investor's position.

Positives

• The filing indicates continued investment by David Capital Partners, a professional investment manager, in LifeCore Biomedical, which may be viewed as a vote of confidence in the company's long-term prospects.
• The passive nature of the investment (below 5% and not for control) suggests a stable shareholder base without immediate activist intentions.

Negatives

• The filing itself does not contain any negative information regarding LifeCore Biomedical's operations or financial performance.

Risks

• The document does not explicitly mention any risks related to LifeCore Biomedical, as it is a disclosure of ownership rather than a comprehensive company report.

Future Outlook

The document does not contain any forward-looking statements or guidance from LifeCore Biomedical's management. It is a disclosure of a passive ownership stake by an investment firm.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Adam J. Patinkin, Managing Member of David Capital Partners, LLC)

Industry Context

This filing is a routine disclosure of a passive investment stake by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics within the biomedical sector, beyond indicating continued institutional interest in LifeCore Biomedical.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a routine disclosure for institutional investors acquiring a passive stake between 5% and 20% (or below 5% if an amendment to a previous filing).
• The 4.87% stake is below the 5% threshold that would typically trigger an initial Schedule 13G filing for a new investor, suggesting this is an amendment to a previously disclosed position or a reduction from a prior stake above 5%.
• The certification that the shares are held for ordinary course of business and not for control is standard for a passive investment firm filing under Rule 13d-1(b).

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, confirming their continued interest without intent to influence control.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this filing, as it pertains solely to a passive ownership disclosure.

Next Steps

• LifeCore Biomedical, Inc. will continue its regular financial reporting (e.g., quarterly 10-Q and annual 10-K filings) as per SEC requirements.
• David Capital Partners, LLC will file future amendments to this Schedule 13G if their beneficial ownership percentage significantly changes (e.g., crosses a 1% threshold up or down, or exceeds 10%).

Key Dates

Keywords

LifeCore Biomedical, David Capital Partners, Schedule 13G, SEC filing, Common Stock, beneficial ownership, investment manager, passive stake, equity investment